# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Roth MKM analyst Jonathan Aschoff maintains Cyclacel Pharmaceuticals (NASDAQ:CYCC) with a Buy and lowers the price target fr...
MMM: 8.3% | 3M shares are trading higher following a Q1 earnings beat, reversing after initially falling. CYCC: 103% | Cyclace...